COVID-associated rhinocerebral mucormycosis: a retrospective analysis of presentation and outcomes

OBJECTIVES: To comprehensively analyse the disease presentation and mortality of COVID-associated rhino-orbito-cerebral mucormycosis. METHODS: A retrospective analysis of the demographics, clinical and radiographic findings was performed. A binary logistic regression analysis was performed to examin...

Descripción completa

Detalles Bibliográficos
Autores principales: Moorthy, Aditya, Nayak, Tulasi, Bachalli, Prithvi S, Tripathi, Krishna Kant, Dutt, Sunil Narayan, Kale, Preeti, Bhat, Prashanth, Suresh, Praveen K, Gaikwad, Rohith, Raju, Arjun, Krishna, Shreya, Conjeevaram, Arvind, Mehta, Sushma, Anil-Kumar, Abhinav, Haldipur, Deepak
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Rhinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289352/
https://www.ncbi.nlm.nih.gov/pubmed/35849188
http://dx.doi.org/10.1007/s00405-022-07544-y
Descripción
Sumario:OBJECTIVES: To comprehensively analyse the disease presentation and mortality of COVID-associated rhino-orbito-cerebral mucormycosis. METHODS: A retrospective analysis of the demographics, clinical and radiographic findings was performed. A binary logistic regression analysis was performed to examine the survival of patients with mucormycosis from hypothesised predictors. RESULTS: A total of 202 patients were included in this study. Statistical significance was demonstrated in the predilection to the male gender, recent history of SARS-COV-2, history of use of corticosteroid and hyperglycemia in this cohort of CAM. The mortality rate was 18.31%. Advanced age, raised HbA1c and intra-orbital extension were found to be predictors adversely affecting survival. CONCLUSION: Early diagnosis, aggressive surgical therapy, early and appropriate medical therapy can help improve outcomes. LEVEL OF EVIDENCE: Level 4.

Ejemplares similares